Pharmacogenetics of naltrexone in asian americans: a randomized placebo-controlled laboratory study.
|Title||Pharmacogenetics of naltrexone in asian americans: a randomized placebo-controlled laboratory study.|
|Publication Type||Journal Article|
|Year of Publication||2012|
|Authors||Ray, LA, Bujarski S, Chin PF, Miotto K|
|Journal||Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology|
|Date Published||2012 Jan|
|Keywords||Adrenocorticotropic Hormone, Adult, Alcohol Dehydrogenase, Alcoholic Intoxication, Alcoholism, Aldehyde Dehydrogenase, Alleles, Asian Americans, Behavior, Addictive, Double-Blind Method, Ethanol, Female, Genotype, Humans, Hydrocortisone, Male, Naltrexone, Narcotic Antagonists, Polymorphism, Single Nucleotide, Receptors, Opioid, mu|
Recent clinical and laboratory studies have shown that the effects of naltrexone for alcoholism may be moderated by the Asn40Asp single-nucleotide polymorphism (SNP) of the μ-opioid receptor gene (OPRM1). Allele frequencies for this polymorphism, however, have been shown to vary substantially as a function of ethnic background, such that individuals of Asian descent are more likely to carry the minor (Asp40) allele. The objective of this study is to test the naltrexone pharmacogenetic effects of the Asn40Asp SNP in a sample of Asian Americans. This study consists of a double-blinded, randomized, placebo-controlled laboratory trial of naltrexone. Participants (n=35, 10 females; 13 Asn40Asn and 22 Asp40 carriers) were non-treatment-seeking heavy drinkers recruited from the community. After taking naltrexone or placebo, participants completed an intravenous alcohol administration session. The primary outcome measures were subjective intoxication and alcohol craving. Results suggested that Asp40 carriers experienced greater alcohol-induced sedation, subjective intoxication, and lower alcohol craving on naltrexone, as compared to placebo, and to Asn40 homozygotes. There results were maintained when controlling for ALDH2 (rs671) and ADH1B (rs1229984) markers and when examining the three levels of OPRM1 genotype, thereby supporting an OPRM1 gene dose response. These findings provide a much-needed extension of previous studies of naltrexone pharmacogenetics to individuals of Asian descent, an ethnic group more likely to express the minor allele putatively associated with improved biobehavioral and clinical response to this medication. These findings help further delineate the biobehavioral mechanisms of naltrexone and its pharmacogenetics.